arrow
E

Eric J. Small

University of California San Francisco
H指数:118
被引数:6.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials

种族与接受阿帕鲁他胺治疗患者生存期的关联:两项III期试验的合并分析

Cancer
IF5.1
2026-01-010
PRE
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer

早期对转移性激素敏感型前列腺癌的 prostate-specific antigen (PSA) 阳性反应预测

2025-12-170
OAAI
Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer

寡转移性前列腺癌管理中,联合或不联合激素疗法进行转移病灶定向放疗的实用性

2025-12-010
PRE
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024

未来晚期前列腺癌临床研究的路线图:2024年晚期前列腺癌共识会议(APCCC)的研究结果

2025-11-210
PRE
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer

基因组规模CRISPR筛选确定PTGES3为晚期前列腺癌雄激素受体功能的直接调节因子

2025-11-050
OAAI
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer

循环肿瘤DNA中的致病基因组改变可预测转移性去势抵抗性前列腺癌患者的总生存期

2025-08-060
PREAI
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer

放疗与手术为基础的治疗策略在高风险前列腺癌中的比较

2025-07-190
PRE
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

转录谱阐明了致死性前列腺癌中恩扎鲁他胺极端无反应的程序

2025-07-070
OAAI
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial

Niraparib和Abiraterone Acetate联合Prednisone治疗转移性去势抵抗性前列腺癌:MAGNITUDE III期试验最终总生存分析

2025-05-050
OAAI
Racial variation in the advanced prostate cancer genome

晚期前列腺癌基因组中的种族差异

2025-03-310
OA
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
2025-03-010
OAAI
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer

转移性去势抵抗性前列腺癌的不良预后基因表达模式

2025-02-220
OAAI
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial

携带BRCA1/2基因变异的转移性去势抵抗性前列腺癌患者报告结局:随机III期MAGNITUDE试验的最终分析

2024-09-230
OAAI
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer
2024-08-130
OAAI
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer

SPARTAN和TITAN晚期前列腺癌患者快速和深度前列腺特异性抗原下降和患者报告的健康相关生活质量的事后分析

2024-08-015
PRE
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer
2024-07-172
OAAI
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study
2024-06-012
OA
An atlas of accessible chromatin in advanced prostate cancer
2024-04-050
PRE